Papanikolaou V, Vrochides D, Margari P, Imvrios G, Papagiannis A, Giakoustidis D, Fouzas I, Antoniadis N, Ouzounidis N, Ntinas A, Vergoulas G, Miserlis G, Solonaki F, Takoudas D
Organ Transplant Unit, Hippokration General Hospital, Thessaloniki, Hellas.
Transplant Proc. 2008 Nov;40(9):3166-9. doi: 10.1016/j.transproceed.2008.09.038.
Although everolimus has proven to be as clinically efficacious as mycophenolate mofetil (MMF), there are reports that proliferation signal inhibitors are associated with poor tolerability. This study reported the experience of a Greek transplant center using either everolimus or MMF in de novo renal transplant recipients. In this retrospective study, a cohort of 40 patients who received everolimus after renal transplant was matched for 10 descriptive parameters with a cohort of another 40 patients who received MMF. The primary endpoint was renal function measured by creatinine and its clearance as well as wound dehiscence and opportunistic infections. The mean creatinine clearance at month 3 was 61.03 +/- 16.99 mL/min versus 60.99 +/- 8.03 for living related recipients on everolimus versus MMF, respectively. The mean creatinine clearance at month 3 was 71.24 +/- 12.61 and 62.61 +/- 20.24 mL/min for cadaveric recipients on everolimus versus MMF, respectively. In addition, the incidence of wound dehiscence was 33.34% versus 3.92% and the incidence of cytomegalovirus infection, 8.33% versus 17.64% for the same two groups, respectively.
尽管依维莫司已被证明在临床上与霉酚酸酯（MMF）一样有效，但有报道称增殖信号抑制剂的耐受性较差。本研究报告了希腊一家移植中心在初发肾移植受者中使用依维莫司或MMF的经验。在这项回顾性研究中，将40例肾移植后接受依维莫司治疗的患者队列与另外40例接受MMF治疗的患者队列在10个描述性参数上进行匹配。主要终点是通过肌酐及其清除率以及伤口裂开和机会性感染来衡量的肾功能。在第3个月时，接受依维莫司治疗的活体亲属受者的平均肌酐清除率为61.03±16.99 mL/分钟，而接受MMF治疗的为60.99±8.03 mL/分钟。在第3个月时，接受依维莫司治疗的尸体供肾受者的平均肌酐清除率分别为71.24±12.61和62.61±20.24 mL/分钟。此外，两组的伤口裂开发生率分别为33.34%和3.92%，巨细胞病毒感染发生率分别为8.33%和17.64%。
